2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - Hall B
This partial session is a mix of important abstracts of molecular observations in MPNs and Histiocytic Disorders. Suggested title (After discussion with other Lead reviewer Florian Heidel:  <blockquote type="cite" style="margin: 0px 10px !important; caret-color: #212121; color: #212121; font-family: Aptos; font-size: 16px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-line: none; text-decoration-thickness: auto; text-decoration-style: solid;"> <div> <div> <div style="direction: ltr; font-family: Aptos, Arial, Helvetica, sans-serif; font-size: 12pt;">Molecular Insights and New Approaches in MPNs</div> </div> </div> </blockquote>
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Biological Therapies, Non-Biological Therapies, Biological Processes, CHIP, Hematopoiesis, Metabolism, Diseases, Genetic Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

926 Digital PCR reveals subclinical JAK2 V617F clones in one in five unaffected relatives of myeloproliferative neoplasms patients

Eli Soyfer, PhD, Xin (Helen) Huang2, Lucas Wadley, PhD, BS3, Madison Fitzsimmons4, Angela Fleischman, MD, PhD5
1 University of California, Irvine, School of Medicine, Irvine, California, United States
2 University of California, Irvine, School of Medicine, Irvine, California, United States
3 University of California, Irvine, School of Medicine, Irvine, California, United States
4 University of California, Irvine, School of Medicine, Irvine, California, United States
5 University of California, Irvine, School of Medicine, Irvine, California, United States
Introduction

First degree relatives of patients with myeloproliferative neoplasms (MPN) carry a 5-to-7-fold elevated risk of developing polycythemia vera or essential thrombocythemia, making them an ideal population for preventative or interventional studies at the pre-clinical stage of disease. JAK2 V617F, the most common MPN driver, is also detectable at low variant allele frequency (VAF) in the general population, where the most sensitively screened cohort reported a prevalence of 3.1%. Whether unaffected MPN relatives carry this clone more often than the general population has not been established. We hypothesized that sensitive screening would reveal subclinical JAK2 V617F in a meaningful fraction of clinically unaffected relatives, identifying an at-risk group missed by standard testing. We tested this using digital PCR (dPCR), supported by a targeted panel to characterize accompanying clonal variation.

Methods

DNA from clinically unaffected relatives of MPN patients was screened for JAK2 V617F by dPCR, scored positive if any replicate reached 0.1% VAF. The 0.1% detection limit of this dPCR assay has been independently validated by our group as previously published (Soyfer et al, 2024). A single molecule molecular inversion probe (smMIP) myeloid panel analyzed with smMIP tools surveyed clonal hematopoiesis across recurrently mutated myeloid genes in a subset of family members, targeting a variant calling sensitivity of 0.2% VAF. The relative JAK2 V617F detection rate was compared against the established general population prevalence of 3.1% by a one sample exact binomial test (Cordua et al, 2019).

Results

Among 66 clinically unaffected relatives screened by dPCR, 13 (19.7%) carried a subclinical JAK2 V617F clone below 2% VAF. This substantially exceeds the established general population prevalence of 3.1% (one sample exact binomial p = 1 x 10?7), with a 95% lower confidence bound of 12.1%, itself several fold above the population rate. Notably, the population prevalence of 3.1% was determined using an assay with a limit of detection comparable to ours, indicating that the higher rate in relatives is unlikely to be explained by differences in assay sensitivity. Clone burden in these relatives ranged from 0.1 to 1.5% VAF, consistent with subclinical clonal hematopoiesis rather than overt disease, supporting our hypothesis that unaffected MPN relatives are enriched for subclinical JAK2 V617F.

smMIP panel sequencing was performed on 20 family members (7 affected patients and 13 unaffected relatives). Clonal variants were detected in 14 individuals, and beyond JAK2 V617F, 6 unaffected relatives carried non driver clonal hematopoiesis mutations in DNMT3A, TET2, ASXL1, IDH1, RUNX1, WT1, EZH2, and GNAS, at VAFs from 0.2 to 14%. The most informative observation came from one family in which three separate unaffected relatives each independently carried CHIP mutations, one with ASXL1 and DNMT3A, one with IDH1 R132C and a TET2 truncation, and one with DNMT3A. This clustering of independent clonal hematopoiesis within a single family suggests a shared predisposition to clonal expansion that extends beyond the JAK2 driver.

Conclusion

Sensitive dPCR screening detects subclinical JAK2 V617F in roughly one in five clinically unaffected relatives of MPN patients, a rate several fold above the established general population prevalence and invisible to less sensitive standard testing. This identifies unaffected relatives as a genetically at-risk group. These individuals also represent an ideal population to follow prospectively for MPN development and for preventative intervention studies. Supporting sequencing data show that clonal hematopoiesis in these families is not limited to JAK2. We are expanding evaluation of other CHIP mutations in MPN family members to determine whether they are more likely to develop CHIP more broadly, and using whole exome sequencing to explore germline variants that may track with MPN and JAK2 V617F associated CHIP.

Eli Soyfer, PhD: No relevant conflicts of interest to declare.